0000899243-22-034377.txt : 20221027
0000899243-22-034377.hdr.sgml : 20221027
20221027215011
ACCESSION NUMBER: 0000899243-22-034377
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221025
FILED AS OF DATE: 20221027
DATE AS OF CHANGE: 20221027
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harrison Seth Loring
CENTRAL INDEX KEY: 0001404955
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 221338846
MAIL ADDRESS:
STREET 1: 230 PARK AVENUE, SUITE 2800
CITY: NEW YORK
STATE: NY
ZIP: 10169
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-10-25
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001404955
Harrison Seth Loring
C/O AKERO THERAPEUTICS, INC.,
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2022-10-25
4
S
0
4515
44.9163
D
300851
D
Common Stock
2022-10-25
4
S
0
4906
44.9163
D
326813
I
See Footnote
Common Stock
2022-10-26
4
S
0
35860
43.0756
D
264991
D
Common Stock
2022-10-26
4
S
0
11539
43.9749
D
253452
D
Common Stock
2022-10-26
4
S
0
18486
44.9002
D
234966
D
Common Stock
2022-10-26
4
S
0
38961
43.0756
D
287852
I
See Footnote
Common Stock
2022-10-26
4
S
0
12537
43.9749
D
275315
I
See Footnote
Common Stock
2022-10-26
4
S
0
20085
44.9002
D
255230
I
See Footnote
Common Stock
2022-10-27
4
S
0
40903
41.1156
D
194063
D
Common Stock
2022-10-27
4
S
0
21830
42.0299
D
172233
D
Common Stock
2022-10-27
4
S
0
3693
43.2321
D
168540
D
Common Stock
2022-10-27
4
S
0
44440
41.1156
D
210790
I
See Footnote
Common Stock
2022-10-27
4
S
0
23719
42.0299
D
187071
I
See Footnote
Common Stock
2022-10-27
4
S
0
4013
43.2321
D
183058
I
See Footnote
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (5), (6), (7), (8), (9) and (10) to this Form 4.
The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. ("ATP GP"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the "LLC"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16") reporting ownership of Common Stock (the "Distribution").
(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution.
Represents shares held directly by the LLC. The reporting person is the manager of the LLC.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.63 to $43.625, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.63 to $44.615, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.635 to $45.14, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.715, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.72 to $42.715, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.495, inclusive.
/s/ Jonathan Young, attorney-in-fact
2022-10-27